Donald Staines
Professor Donald R. Staines, MBBS, MPH, FAFPHM, FAFOEM, is a Clinical Professor at Menzies Health Institute Queensland and the co-director (alongside Sonya Marshall-Gradisnik) of the National Centre for Neuroimmunology and Emerging Diseases (NCNED) at Griffith University in Queensland in north-eastern Australia.[1] His research team is working towards discovery of diagnostic tools and treatments for chronic fatigue syndrome.[2]
International Consensus Criteria[edit | edit source]
He is one of the authors of the 2011 case definition, International Consensus Criteria.[3]
Diagnostic test[edit | edit source]
In February 2016 the research team led by Donald Staines and Sonya Marshall-Gradisnik announced it had created a diagnostic test for the disease using CD8 T cells.[4] They have been awarded a $4-million grant to be administered during the next five years that will enable them to continue research into developing a diagnostic test for ME/CFS.[5]
Open Letters to The Lancet[edit | edit source]
Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Staines, along with 41 colleagues in the ME/CFS field, signed the second letter. In June 2018, Dr. Staines signed the third letter, this time along with approximately 100 colleagues.
- 10 February 2016, An open letter to The Lancet, again - Virology blog
- 19 June 2018, Trial By Error: An Open Letter to The Lancet, Two Years On - Virology blog
Notable studies[edit | edit source]
- 2011, Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[6] (Full Text)
- 2012, The Effects of Influenza Vaccination on Immune Function in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[7] (Full Text)
- 2014, Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[8] (Full Text)
- 2014, The Role of Adaptive and Innate Immune Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[9] (Full Text)
- 2014, The role of clinical guidelines for chronic fatigue syndrome/myalgic encephalomyelitis in research settings[10]
- 2014, Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[11] (Full Text)
- 2015, A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients[12]
- 2015, Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients[13] (Abstract)
- 2015, Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[14] (Full Text)
- 2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients[15] (Full Text)
- 2015, Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[16] (Full Text)
- 2015, Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[17] (Full Text)
- 2015, Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[18]
- 2016, Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[19] (Full Text)
- 2016, A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[20] (Abstract)
- 2016, Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study[21] (Full Text)
- 2016, Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison.[22] (Full Text)
- 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[23] (Full Text)
- 2016, Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome[24] (Full Text)
- 2017, Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels[25] (Full Text)
- 2017, Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients[26] (Full Text)
- 2018, Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[27] (Full text)
- 2018, Brain function characteristics of chronic fatigue syndrome: A task fMRI study[28] (Full Text)
- 2018, A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).[29] (Abstract)
- 2018, Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation[30] (Full Text)
- 2018, Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation[31] (Abstract)
Talks and interviews[edit | edit source]
- 2015, Who Are You? Professor Don Staines, ME/CFS research, Griffith University Gold Coast (31 August 2015)
- 2016, Speaker at the 11th Invest in ME International ME Conference on "Update from NCNED: Receptor identification and intracellular signalling"[32] DVD available
- 2017, Speaker at the 12th Invest in ME International ME Conference on "Dysregulation of Transient Receptor Potential (TRP) ion channels and calcium in natural killer cells in CFS/ME patients"[33] - DVD available
Learn more[edit | edit source]
- Donald Staines Griffith University - Donald Staines
- 2014, Gold Coast’s Griffith University to lead way in the battle against chronic fatigue (Gold Coast Bulletin, July 30 2014)
- 2016, Australian scientists make breakthrough in Chronic Fatigue Syndrome testing
Online presence[edit | edit source]
See also[edit | edit source]
- Sonya Marshall-Gradisnik
- Invest in ME International ME Conference
- National Centre for Neuroimmunology and Emerging Diseases
References[edit | edit source]
- ↑ https://www.griffith.edu.au/health/national-centre-neuroimmunology-emerging-diseases/our-team
- ↑ https://www.goldcoastbulletin.com.au/lifestyle/gold-coast-team-getting-closer-to-discovering-test-for-chronic-fatigue-syndrom/news-story/1627b3fcc41c53efac927200a53cc756
- ↑ Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, A C P; Speight, N; Vallings, R; Bateman, L; Baumgarten-Austrheim, B; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Jo, D; Lewis, D; Light, A; Marshall-Gradisnik, S; Mena, I; Mikovits, JA; Miwa, K; Murovska, M; Pall, ML; Stevens, S (2011), "Myalgic encephalomyelitis: International Consensus Criteria.", Journal of Internal Medicine, 270 (4): 327-38, doi:10.1111/j.1365-2796.2011.02428.x, PMID 21777306
- ↑ Australian scientists make breakthrough in Chronic Fatigue Syndrome testing, ABC News (Australia), 29 February 2016
- ↑ http://www.goldcoastbulletin.com.au/lifestyle/gold-coast-team-getting-closer-to-discovering-test-for-chronic-fatigue-syndrom/news-story/1627b3fcc41c53efac927200a53cc756
- ↑ Brenu, EW; van Driel, ML; Staines, DR; Ashton, KJ; Ramos, SB; Keane, J; Klimas, NG; Marshall-Gradisnik, SM (2011), "Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Journal of Translational Medicine, 9 (81), doi:10.1186/1479-5876-9-81
- ↑ Brenu, Ekua W; van Driel, Mieke L; Staines, Donald R; Kreijkamp-Kaspers, Sanne; Hardcastle, Sharni L; Marshall-Gradisnik, Sonya M (2012), "The Effects of Influenza Vaccination on Immune Function in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis" (PDF), International Journal of Clinical Medicine, 3 (6): 544-551, doi:10.4236/ijcm.2012.36098
- ↑ Huth, Teilah K.; Brenu, Ekua; Nguyen, Thao; Hardcastle, Sharni L.; Johnston, Samantha; Ramos, Sandra; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2014), "Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Journal of Clinical & Cellular Immunology, 5 (3), doi:10.4172/2155-9899.1000223
- ↑ Brenu, EW; Huth, TK; Hardcastle, SL; Fuller, K; Kaur, M; Johnston, S; Ramos, S; Staines, D; Marshall-Gradisnik, S (2014), "The Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis", International Immunology, 26 (4): 233-42, doi:10.1093/intimm/dxt068, PMID 24343819
- ↑ Johnston, S.C.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (2014), "The role of clinical guidelines for chronic fatigue syndrome/myalgic encephalomyelitis in research settings.", Fatigue: Biomedicine, Health & Behavior, 2 (1): 28-39, doi:10.1080/21641846.2013.860779
- ↑ Hardcastle, Sharni L.; Brenu, Ekua W.; Johnston, Samantha; Nguyen, Thao; Huth, Teilah K.; Kaur, Manprit; Ramos, Sandra; Salajegheh, Ali; Staines, Donald R.; Marshall-Gradisnik, Sonya (2014), "Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", Journal of Clinical & Cellular Immunology, 5 (190), doi:10.4172/2155-9899.1000190
- ↑ Wong, Naomi; Nguyen, Thao; Brenu, Ekua Weba; Broadley, Simon; Staines, Donald; Marshall-Gradisnik, Sonya (2015), "A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients", International Journal of Clinical Medicine, 6 (10): 769-783, doi:10.4236/ijcm.2015.610103
- ↑ Armstrong, Christopher W.; McGregor, Neil R.; Lewis, Donald P.; Butt, Henry L.; Gooley, Paul R. (2015), "Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients", Metabolomics, 11 (6): 1626–1639, doi:10.1007/s11306-015-0816-5
- ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015), "Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients", International Journal of Medical Sciences, 12 (10): 764-772, doi:10.7150/ijms.12399
- ↑ Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (2015), "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients", Immunology and Immunogenetics Insights, 2015 (7): 1-6, doi:10.4137/III.S25147
- ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015), "Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", BMC Immunology, 16 (35), doi:10.1186/s12865-015-0101-4
- ↑ Hardcastle, Sharni Lee; Brenu, Ekua Weba; Johnston, Samantha; Nguyen, Thao; Huth, Teilah; Ramos, Sandra; Staines, Donald; Marshall-Gradisnik, Sonya (2015), "Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients", Journal of Translational Medicine, 13 (299), doi:10.1186/s12967-015-0653-3
- ↑ Peterson, D; Brenu, EW; Gottschalk, G; Ramos, Sandra B; Nguyen, T; Staines, D; Marshall-Gradisnik, S (2015), "Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Mediators of Inflammation, 2015, doi:10.1155/2015/929720
- ↑ Huth, T.K.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (2016), "Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients", Gene Regulation and Systems Biology, 10: 43–49, doi:10.4137/GRSB.S39861
- ↑ Collatz, Ansel; Johnston, Samantha C.; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2016), "A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Clinical Therapeutics, 38 (6): 1263-1271.e9, doi:10.1016/j.clinthera.2016.04.038, PMID 27229907
- ↑ Shan, Zack Y.; Kwiatek, Richard; Burnet, Richard; Del Fante, Peter; Staines, Donald R.; Marshall‐Gradisnik, Sonya; Barnden, Leighton R. (2016), "Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study", Journal of Magnetic Resonance Imaging, 44: 1301–1311, doi:10.1002/jmri.25283
- ↑ Ramos, S; Brenu, E; Broadley, S; Kwiatek, R; Ng, J; Nguyen, T; Freeman, S; Staines, D; Marshall-Gradisnik, S (March 20, 2016), "Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison", Asian Pac J Allergy Immunol, doi:10.12932/AP0733
- ↑ Huth, Teilah K.; Staines, Donald; Marshall-Gradisnik, Sonya (2016), "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients", Journal of Translational Medicine, 14 (97), doi:10.1186/s12967-016-0859-z
- ↑ Marshall-Gradisnik, Sonya M.; Huth, Teilah; Chacko, Anu; Johnston, Samantha; Smith, Peter; Staines, Donald R. (2016), "Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome", The Application of Clinical Genetics, 9: 39—47, doi:10.2147/TACG.S99405
- ↑ Nguyen, T.; Hardcastle, S.; Clarke, L.; Smith, P.; Staines, D.; Marshall-Gradisnik, S. (2017), "Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels", Clinical and Experimental Immunology, 187 (2): 284–293, doi:10.1111/cei.12882
- ↑ Nguyen, T.; Johnston, S.; Chacko, A.; Gibson, D.; Cepon, J.; Smith, D.; Staines, D.; Marshall-Gradisnik, S. (2017), "Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients", Asian Pac J Allergy Immunol, 35 (2): 75-81, doi:10.12932/AP0771
- ↑ Marshall-Gradisnik, S. , Fretel, M. , Eaton, N. , Cabanas, H. , Balinas, C. , Gopalan, V. , Petersen, D. , Passmore, R. , Tang, K. , Haque, M. , Lam, A. and Staines, D. (2018) Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. International Journal of Clinical Medicine, 9, 467-480. doi: 10.4236/ijcm.2018.95040.
- ↑ Shan, Zack Y.; Finegan, Kevin; Bhuta, Sandeep; Ireland, Timothy; Staines, Donald R.; Marshall‐Gradisnik, Sonya; Barnden, Leighton R. (2018), "Brain function characteristics of chronic fatigue syndrome: A task fMRI study", NeuroImage: Clinical, 19: 279-286, doi:10.1016/j.nicl.2018.04.025
- ↑ Corbitt, M; Campagnolo, N; Staines, D; Marshall-Gradisnik, S (2018), "A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", Probiotics Antimicrob Proteins, doi:10.1007/s12602-018-9397-8
- ↑ Eaton, Natalie; Cabanas, Hélène; Balinas, Cassandra; Klein, Anne; Staines, Donald R.; Marshall-Gradisnik, Sonya (2018), "Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation", BMC Pharmacology & Toxicology, 19 (12), doi:10.1186/s40360-018-0203-8, PMID 29587879
- ↑ Nguyen, T.; Staines, D.; Johnston, S.; Marshall-Gradisnik, S. (July 2018), "Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation", Asian Pac J Allergy Immunol, doi:10.12932/AP-011117-0188
- ↑ http://www.investinme.eu/IIMEC11.shtml#agenda
- ↑ http://www.investinme.eu/iimec12.shtml